Literature DB >> 33807522

Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History.

Hideaki Kaneto1, Tomohiko Kimura1, Atsushi Obata1, Masashi Shimoda1, Kohei Kaku1.   

Abstract

While there are various kinds of drugs for type 2 diabetes mellitus at present, in this review article, we focus on metformin which is an insulin sensitizer and is often used as a first-choice drug worldwide. Metformin mainly activates adenosine monophosphate-activated protein kinase (AMPK) in the liver which leads to suppression of fatty acid synthesis and gluconeogenesis. Metformin activates AMPK in skeletal muscle as well, which increases translocation of glucose transporter 4 to the cell membrane and thereby increases glucose uptake. Further, metformin suppresses glucagon signaling in the liver by suppressing adenylate cyclase which leads to suppression of gluconeogenesis. In addition, metformin reduces autophagy failure observed in pancreatic β-cells under diabetic conditions. Furthermore, it is known that metformin alters the gut microbiome and facilitates the transport of glucose from the circulation into excrement. It is also known that metformin reduces food intake and lowers body weight by increasing circulating levels of the peptide hormone growth/differentiation factor 15 (GDF15). Furthermore, much attention has been drawn to the fact that the frequency of various cancers is lower in subjects taking metformin. Metformin suppresses the mechanistic target of rapamycin (mTOR) by activating AMPK in pre-neoplastic cells, which leads to suppression of cell growth and an increase in apoptosis in pre-neoplastic cells. It has been shown recently that metformin consumption potentially influences the mortality in patients with type 2 diabetes mellitus and coronavirus infectious disease (COVID-19). Taken together, metformin is an old drug, but multifaceted mechanisms of action of metformin have been unraveled one after another in its long history.

Entities:  

Keywords:  AMPK; COVID-19; GDF15; autophagy; glucagon signaling; gut microbiome; mTOR; metformin

Mesh:

Substances:

Year:  2021        PMID: 33807522      PMCID: PMC7962041          DOI: 10.3390/ijms22052596

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  108 in total

Review 1.  Minireview: Autophagy in pancreatic β-cells and its implication in diabetes.

Authors:  Hirotaka Watada; Yoshio Fujitani
Journal:  Mol Endocrinol       Date:  2015-01-29

Review 2.  Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.

Authors:  C J Bailey
Journal:  Diabetes Obes Metab       Date:  2005-11       Impact factor: 6.577

3.  Type 2 diabetes-a matter of beta-cell life and death?

Authors:  Christopher J Rhodes
Journal:  Science       Date:  2005-01-21       Impact factor: 47.728

4.  Endothelial insulin receptors differentially control insulin signaling kinetics in peripheral tissues and brain of mice.

Authors:  Masahiro Konishi; Masaji Sakaguchi; Samuel M Lockhart; Weikang Cai; Mengyao Ella Li; Erica P Homan; Christian Rask-Madsen; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

5.  Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.

Authors:  Satoshi Kawashima; Taka-aki Matsuoka; Hideaki Kaneto; Yoshihiro Tochino; Ken Kato; Kaoru Yamamoto; Tsunehiko Yamamoto; Munehide Matsuhisa; Iichiro Shimomura
Journal:  Biochem Biophys Res Commun       Date:  2010-12-07       Impact factor: 3.575

6.  MafA is critical for maintenance of the mature beta cell phenotype in mice.

Authors:  Wataru Nishimura; Satoru Takahashi; Kazuki Yasuda
Journal:  Diabetologia       Date:  2014-12-13       Impact factor: 10.122

7.  Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation.

Authors:  Zhengyu Liu; Joel F Habener
Journal:  J Biol Chem       Date:  2008-01-23       Impact factor: 5.157

8.  Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.

Authors:  Seizo Okauchi; Masashi Shimoda; Atsushi Obata; Tomohiko Kimura; Hidenori Hirukawa; Kenji Kohara; Tomoatsu Mune; Kohei Kaku; Hideaki Kaneto
Journal:  Biochem Biophys Res Commun       Date:  2015-10-23       Impact factor: 3.575

9.  Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.

Authors:  Russell A Miller; Qingwei Chu; Jianxin Xie; Marc Foretz; Benoit Viollet; Morris J Birnbaum
Journal:  Nature       Date:  2013-01-06       Impact factor: 49.962

10.  Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression.

Authors:  Ian Huang; Michael Anthonius Lim; Raymond Pranata
Journal:  Diabetes Metab Syndr       Date:  2020-04-17
View more
  13 in total

Review 1.  Diabetic Muscular Atrophy: Molecular Mechanisms and Promising Therapies.

Authors:  Yuntian Shen; Ming Li; Kexin Wang; Guangdong Qi; Hua Liu; Wei Wang; Yanan Ji; Mengyuan Chang; Chunyan Deng; Feng Xu; Mi Shen; Hualin Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

2.  Potential Benefits of Combined Statin and Metformin Therapy on Resistance Training Response in Older Individuals.

Authors:  Douglas E Long; Kate Kosmac; Cory M Dungan; Marcas M Bamman; Charlotte A Peterson; Philip A Kern
Journal:  Front Physiol       Date:  2022-04-14       Impact factor: 4.755

Review 3.  An update on mode of action of metformin in modulation of meta-inflammation and inflammaging.

Authors:  Meysam Khodadadi; Davoud Jafari-Gharabaghlou; Nosratollah Zarghami
Journal:  Pharmacol Rep       Date:  2022-01-24       Impact factor: 3.024

4.  Changing prostaglandin E2 (PGE2) signaling during lesional progression and exacerbation of endometriosis by inhibition of PGE2 receptor EP2 and EP4.

Authors:  Qingqing Huang; Xishi Liu; Sun-Wei Guo
Journal:  Reprod Med Biol       Date:  2021-12-02

Review 5.  Integrated or Independent Actions of Metformin in Target Tissues Underlying Its Current Use and New Possible Applications in the Endocrine and Metabolic Disorder Area.

Authors:  Giovanni Tulipano
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

6.  Metformin Reduces Repeat Mild Concussive Injury Pathophysiology.

Authors:  Erica L Underwood; John B Redell; Mark E Maynard; Nobuhide Kobori; Michael J Hylin; Kimberly N Hood; Rebecca K West; Jing Zhao; Anthony N Moore; Pramod K Dash
Journal:  eNeuro       Date:  2022-01-13

7.  Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells.

Authors:  Bao-Jin Chi; Yao Sun; Ling-Li Quan; Jin-Tao Zhao; Bo Wei; Shu-Qiu Wang
Journal:  Dis Markers       Date:  2022-06-24       Impact factor: 3.464

Review 8.  Research progress of coumarins and their derivatives in the treatment of diabetes.

Authors:  Yinbo Pan; Teng Liu; Xiaojing Wang; Jie Sun
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

9.  Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.

Authors:  Abira Usman; Kevin P Bliden; Alastair Cho; Naval Walia; Christophe Jerjian; Arvind Singh; Parshotam Kundan; Sanchit Duhan; Udaya S Tantry; Paul A Gurbel
Journal:  J Thromb Thrombolysis       Date:  2022-01-18       Impact factor: 5.221

Review 10.  Metformin: Sex/Gender Differences in Its Uses and Effects-Narrative Review.

Authors:  Ioannis Ilias; Manfredi Rizzo; Lina Zabuliene
Journal:  Medicina (Kaunas)       Date:  2022-03-16       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.